Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus TREST.
HALOTESTIN vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category C
Category C
Androgen
Androgen